Gladstone NOW: The Campaign Join Us on the Journey✕
1 - 6 of 6 Results Clear All
The annual event hosted by Gladstone Institutes showcases its most promising scientific discoveries for interested investors and potential industry partners
Corporate Liaison and Ventures Business Development Institutional News
A research collaboration to target the protein tau with small molecules
Business Development News Release Alzheimer’s Disease Neurological Disease Mucke Lab
Senior Investigator Katerina Akassoglou has fundamentally changed the way scientists think of neurological disorders. She made the seminal discovery that blood leaks are toxic to the brain by promoting inflammation and destroying neurons. Her research led the scientific community to reassess the complex relationship between the brain, immune, and vascular systems.
Business Development Institutional News Assay Development and Drug Discovery Core Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab
BioMotiv and Cure Network Dolby Acceleration Partners collaborate to advance the development of better treatments for brain disorders
Corporate Liaison and Ventures Business Development News Release Alzheimer’s Disease Epilepsy Neurological Disease Palop Lab
Study will use innovative technology to focus on neurodegenerative diseases
Business Development News Release Alzheimer’s Disease Finkbeiner Lab
SAN FRANCISCO and PRINCETON, NJ—December 22, 2011—Bristol-Myers Squibb Company (NYSE:BMY) and the Gladstone Institutestoday announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.
Business Development
